CYP2C19 and acute myeloid leukemia: Based on the above observations and the typical plasma concentrations (5 to 50 nM) of AML [17,37], its enantiomers can be regarded as weak to moderate inhibitors of CYP2C9 and CYP2C19 that exhibit stereoselective patterns only under special conditions (drug accumulation, overdosing, etc.).